tiprankstipranks
Trending News
More News >

Cyclopharm Limited’s 2024 Annual Report Highlights Global Leadership in Lung Imaging

Story Highlights
Cyclopharm Limited’s 2024 Annual Report Highlights Global Leadership in Lung Imaging

Confident Investing Starts Here:

An announcement from Cyclopharm Limited ( (AU:CYC) ) is now available.

Cyclopharm Limited has released its 2024 Annual Report, highlighting its position as a global leader in functional lung ventilation imaging. The report underscores the company’s commitment to innovation and its strong market presence with Technegas™, which is widely used in 66 countries, reflecting its significant impact on the healthcare industry.

More about Cyclopharm Limited

Cyclopharm Limited is a health technology company specializing in functional lung ventilation imaging. Its proprietary product, Technegas™, is a leader in diagnostic imaging and is available in 66 countries.

YTD Price Performance: -24.05%

Average Trading Volume: 164,691

Technical Sentiment Signal: Buy

Current Market Cap: A$133.4M

For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App